Neoadjuvant androgen deprivation for prostate volume reduction: the optimal duration in prostate cancer radiotherapy (Q84066528)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19523856%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

title

Neoadjuvant androgen deprivation for prostate volume reduction: the optimal duration in prostate cancer radiotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19523856%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

author name string

Johan F Langenhuijsen

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19523856%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Emile N van Lin

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19523856%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Aswin L Hoffmann

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19523856%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Ilse Spitters-Post

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19523856%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

J Alfred Witjes

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19523856%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Johannes H Kaanders

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19523856%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Peter F Mulders

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19523856%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

publication date

12 June 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19523856%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19523856%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19523856%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19523856%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

page(s)

52-57

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19523856%20AND%20SRC:MED&resulttype=core&format=json

Combined castration and fractionated radiotherapy in an experimental prostatic adenocarcinoma

31 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.024

Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.024

Radiation therapy combined with hormone therapy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.024

American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.024

The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.024

Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.024

Results of 3D conformal radiotherapy in the treatment of localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.024

High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.024

Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.024

Dose response in prostate cancer with 8-12 years' follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.024

Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.024

Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.024

Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.024

Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.024

Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.024

Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.024

Prostate position relative to pelvic bony anatomy based on intraprostatic gold markers and electronic portal imaging.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.024

The effect of an endorectal balloon and off-line correction on the interfraction systematic and random prostate position variations: a comparative study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.024

Clinical application of a repositioning scheme, using gold markers and electronic portal imaging.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.024

The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformal treatment planning for stage C prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.024

Neoadjuvant hormonal downsizing of localized carcinoma of the prostate: effects on the volume of normal tissue irradiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.024

Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.024

Changes in treatment volume of hormonally treated and untreated cancerous prostate and its impact on rectal dose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.024

Computed tomography/magnetic resonance based volume changes of the primary tumour in patients with prostate cancer with or without androgen deprivation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.024

Prostate volumes defined by magnetic resonance imaging and computerized tomographic scans for three-dimensional conformal radiotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.024

Definition of the prostate in CT and MRI: a multi-observer study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.024

Prostate volume determination: differential volume measurements comparing CT and TRUS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.024

Comparability of CT-based and TRUS-based prostate volumes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.024

The role of androgen deprivation therapy combined with prostate brachytherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.024

Does a delay between diagnosis and radical prostatectomy increase the risk of disease recurrence?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.024

Impact of surgical delay on long-term cancer control for clinically localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.024

Delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.024

Does the time from biopsy to surgery affect biochemical recurrence after radical prostatectomy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.024

Reasonable delay of surgical treatment in men with localized prostate cancer--impact on prognosis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.024

Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.024

The impact of a delay in initiating radiation therapy on prostate-specific antigen outcome for patients with clinically localized prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.03.024

10.1016/J.UROLONC.2009.03.024

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19523856%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

1 reference